Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Biochemical recurrence of prostate cancer, drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether treating PSMA PET-detected metastases early lengthens life or only lowers PSA.
Background: Oligometastatic disease. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
How to spare men with slow doubling times from years of hormone therapy.
The trials that defined recurrence used conventional imaging; PSMA PET restages many of these men as metastatic.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
MFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.